310 related articles for article (PubMed ID: 26296187)
21. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Friedlander M; Hancock KC; Rischin D; Messing MJ; Stringer CA; Matthys GM; Ma B; Hodge JP; Lager JJ
Gynecol Oncol; 2010 Oct; 119(1):32-7. PubMed ID: 20584542
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
23. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
24. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
[TBL] [Abstract][Full Text] [Related]
25. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
[TBL] [Abstract][Full Text] [Related]
26. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
27. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
28. Pazopanib: a Review in Advanced Renal Cell Carcinoma.
Frampton JE
Target Oncol; 2017 Aug; 12(4):543-554. PubMed ID: 28664385
[TBL] [Abstract][Full Text] [Related]
29. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
Sonpavde G; Hutson TE; Sternberg CN
Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
[TBL] [Abstract][Full Text] [Related]
30. Effect of pazopanib on tumor microenvironment and liposome delivery.
Tailor TD; Hanna G; Yarmolenko PS; Dreher MR; Betof AS; Nixon AB; Spasojevic I; Dewhirst MW
Mol Cancer Ther; 2010 Jun; 9(6):1798-808. PubMed ID: 20515941
[TBL] [Abstract][Full Text] [Related]
31. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Podar K; Tonon G; Sattler M; Tai YT; Legouill S; Yasui H; Ishitsuka K; Kumar S; Kumar R; Pandite LN; Hideshima T; Chauhan D; Anderson KC
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19478-83. PubMed ID: 17164332
[TBL] [Abstract][Full Text] [Related]
32. Overview of anti-angiogenic agents in development for ovarian cancer.
Burger RA
Gynecol Oncol; 2011 Apr; 121(1):230-8. PubMed ID: 21215996
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic therapies in epithelial ovarian cancer.
Teoh DG; Secord AA
Cancer Control; 2011 Jan; 18(1):31-43. PubMed ID: 21273978
[TBL] [Abstract][Full Text] [Related]
34. The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.
Chellappan DK; Chellian J; Ng ZY; Sim YJ; Theng CW; Ling J; Wong M; Foo JH; Yang GJ; Hang LY; Nathan S; Singh Y; Gupta G
Biomed Pharmacother; 2017 Dec; 96():768-781. PubMed ID: 29054093
[TBL] [Abstract][Full Text] [Related]
35. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
Arai H; Fukasawa N; Ueta F
Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):37-42. PubMed ID: 23302947
[No Abstract] [Full Text] [Related]
37. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A; Mariani L; Zaffaroni N; Schwartz LH; Giannatempo P; Crippa F; Morosi C; Lanocita R; Sava T; Ortega C; Messina C; Sacco C; Pennati M; Daidone MG; Nicolai N; De Braud F; Gianni AM; Salvioni R
Lancet Oncol; 2012 Aug; 13(8):810-6. PubMed ID: 22819172
[TBL] [Abstract][Full Text] [Related]
38. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
[TBL] [Abstract][Full Text] [Related]
39. The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.
Gril B; Palmieri D; Qian Y; Anwar T; Ileva L; Bernardo M; Choyke P; Liewehr DJ; Steinberg SM; Steeg PS
PLoS One; 2011; 6(10):e25625. PubMed ID: 21998674
[TBL] [Abstract][Full Text] [Related]
40. Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma.
Yanagisawa R; Noguchi M; Fujita K; Sakashita K; Sano K; Ogiso Y; Katsuyama Y; Kondo Y; Komori K; Fujihara I; Kitamura R; Hiroma T; Nakamura T
Pediatr Blood Cancer; 2016 Feb; 63(2):348-51. PubMed ID: 26375879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]